Targets › AAK1
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Mar 2027.
Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis. Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1. (UniProt, Q2M2I8)
Open in Phaseline: the race on AAK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Satellos Bioscience | SAT-3247 AAK1 inhibitor that promotes functional rescue of asymmetric satellite cell division | AAK1 | Phase 2 | Duchenne Muscular Dystrophy | Mar 2027 |
Duchenne Muscular Dystrophy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.